Science and Research

Our Pipeline  

Beginning with patients’ needs, we build our pipeline by identifying the most promising science and collaborate with leading teams around the globe to accelerate innovation. Our oncology R&D activities are focused on translating science into curative or transformative potential treatments by targeting tumor vulnerabilities and through novel strategies that leverage the power of innate immunity. 

These therapies in development are investigational and have not been approved by any regulatory bodies for use in the investigational indications listed below.

Investigational Therapy

Platform

Investigational Indication

Phase

Brigatinib*

Targeted therapy

2L ALK+ non-small cell lung cancer (GL)

Phase 3

Targeted therapy

1L & 2L ALK+ non-small cell lung cancer (CN)

Filed

Description: 

ALK inhibitor 

Cabozantinib*

Targeted therapy

Metastatic castration-​resistant prostate cancer (JP)

Phase 3

Targeted therapy

2L metastatic non-small cell lung cancer (JP)

Phase 3

Description

Tyrosine kinase inhibitor including MET/AXL/VEGFR 

Additional information: 

Cabozantinib is being developed in Japan in collaboration with Exelixis. 

Ixazomib*

Proteasome inhibitor

Maint. newly diagnosed multiple myeloma post- stem cell transplant (US, EU)

Phase 3

Proteasome inhibitor

Maint. newly diagnosed multiple myeloma without stem cell transplant (US, EU, CN)

Phase 3

Description: 

Proteasome inhibitor 

Mobocertinib

Targeted therapy

2L EGFR Exon20 insertion non-small cell lung cancer (EU, CN)

Filed

Targeted therapy

1L EGFR Exon20 insertion non-small cell lung cancer (US, EU, GEM)

Phase 3

Description:

Oral EGFR Exon20 tyrosine kinase inhibitor

Ponatinib*

Targeted therapy

FL Ph+ acute lymphocytic leukemia (US)

Phase 3

Description: 

BCR-ABL inhibitor 

Additional information:

Takeda shares development rights with Incyte Corp. (Europe, Turkey and Israel) and Otsuka Pharm. (Asia Pacific territories). 

Relugolix* (TAK-385)

Small molecule

Prostate cancer (JP, Asian countries)

Phase 3

Description: 

GnRH Antagonist 

Additional information: 

Relugolix is being developed in Japan and Asian countries in collaboration with Myovant Sciences, Inc. 

Pevonedistat (TAK-924)

Targeted therapy

Acute myeloid leukemia**

Phase 2

Description:

NEDD8-activating enzyme inhibitor

**This trial is not registration-enabling.

TAK-007

I-O redirected immunity

B-cell malignancies

Phase 1/2

Description: 

CD19 CAR NK 

Additional information: 

TAK-007 is being developed in collaboration with The University of Texas MD Anderson Cancer Center.  

TAK-186

I-O redirected immunity

EGFR-expressing solid tumors

Phase 1/2

Description: 

EGFR x CD3 COBRA™ molecule (conditionally active bispecific T-cell engager immunotherapy) 

TAK-573

I-O cold-to-hot

Multiple myeloma

Phase 1/2

I-O cold-to-hot

Solid tumors

Phase 1/2

Description:

Anti-CD38 Attenukine™

Additional information: 

TAK-573 was licensed from Teva Pharmaceuticals. Attenukine is a trademark of Teva Pharmaceutical Industries Ltd.

TAK-605

I-O cold-to-hot

Solid tumors

Phase 1/2

Description: 

Armored oncolytic virus 

Additional information: 

TAK-605 is being developed in collaboration with Turnstone Biologics.  

TAK-981

I-O cold-to-hot

Non-Hodgkin lymphoma

Phase 1/2

I-O cold-to-hot

Multiple myeloma

Phase 1/2

I-O cold-to-hot

Solid tumors

Phase 1/2

Description: 

SUMOylation inhibitor 

TAK-102

I-O redirected immunity

Solid tumors

Phase 1

Description: 

GPC3 CAR-T 

Additional information: 

TAK-102 is being developed in collaboration with Noile-Immune Biotech.  

TAK-252

I-O cold-to-hot

Solid tumors

Phase 1

Description: 

Bifunctional checkpoint modulator 

Additional information: 

TAK-252 is being developed in collaboration with Shattuck Labs.  

TAK-676

I-O cold-to-hot

Solid tumors

Phase 1

Description: 

IV STING agonist 

TAK-940

I-O redirected immunity

B-cell malignancies

Phase 1

Description: 

CD19-1XX CAR-T 

Additional information: 

TAK-940 is being developed in collaboration with Memorial Sloan Kettering Cancer Center.  

*Marketed products have received approval in one or more jurisdictions.
All programs have global development rights unless otherwise noted.
GL = global (USA, Europe, Japan, China) / EU = Europe / JP = Japan / CN = China / GEM = global emerging markets

Investors

To learn more about Oncology-specific Investor events and information, visit the Takeda Oncology Investor Relations page

Explore More

Newsroom

Keep up on the latest Oncology news by visiting our newsroom

Partnership Strategy

We believe the best way to achieve our aspiration to cure cancer is by working together

R&D Approach

Decades of leadership in Oncology with a diverse and robust pipeline